Base de dados : LILACS
Pesquisa : D12.776.503.307.300 [Categoria DeCS]
Referências encontradas : 9 [refinar]
Mostrando: 1 .. 9   no formato [Detalhado]

página 1 de 1

  1 / 9 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1104226
Autor: Pavlov, Sergey; Babenko, Nataliia; Kumetchko, Marina; Litvinova, Olga; Semko, Natalia; Pavlova, Olga.
Título: Intercellular mediators in bone remodeling regulation in the experimental renal pathology / Mediadores intercelulares de la regulación de la remodelación ósea en un modelo experimental de patología renal
Fonte: Actual. osteol;15(3):180-191, Sept-Dic. 2019. ilus.
Idioma: en.
Resumo: Bone metabolism disorders are characterized by an imbalance of bone resorption and formation in the bone remodeling process. Glucocorticoids that are used to treat kidney diseases exacerbate these disorders. P-selectin and galectin-3 are molecules involved in the sclerotic process in kidney, whereas bone resorption is regulated by the interaction between the nuclear factor activator kappa b receptor (RANK), its ligand (RANKL) and the RANKL decoy receptor osteoprotegerin (OPG). The aim of this study was to investigate the cellular and molecular mechanisms of disruption of bone remodeling regulation processes, reflected by intercellular mediators (RANKL, OPG, P-selectin and galectin-3) in chronic kidney disease experimental model treated with glucocorticoids. Rats were divided into four groups of 10 animals each. The first group, the control group, included intact animals. The second group consisted of rats with impaired bone remodeling resulting from chronic kidney disease (experimental group (CKD). The third group was a group of animals with impaired bone remodeling due to exposure to glucocorticoids (experimental group (GCs)). The fourth group consisted of rats with impaired bone remodeling in chronic kidney disease, followed by exposure to glucocorticoids (experimental group (CKD + GCs)). The effects of CKD and glucocorticoid were evaluated biochemically, histologically and by measuring bone density. An enzymelinked immunoassay was used to measure intercellular mediator levels in the serum. The bone density in the experimental groups was reduced compared to the control group. RANKL levels in animals of three experimental groups were higher than in intact animals. Serum levels of OPG were higher in CKD and GCs groups than in intact animals. At the same time, in the animals' blood serum of the CKD + GCs group, the levels of OPG were lower, than those in animals from the control group. The levels of galectin-3 in the serum of the experimental groups GCs and CKD + GCs were lower than in intact animals. The serum levels of galectin-3 in animals of the CKD group were higher than those in animals from the control group. The levels of P-selectin were lower in the serum of the GCs group than in intact animals. At the same time, the levels of P-selectin were higher in the CKD and CKD + GCs groups, than those in animals from the control group. In conclusion, the study of the complex system of bone remodeling regulation, which includes many factors and their interactions, may lead to the development of new methods for treating patients with chronic kidney disease in order to prevent osteoporosis in the future. (AU)

Las enfermedades metabólicas óseas se caracterizan por un desequilibrio en el proceso de remodelación ósea en los que participan mediadores tales como receptor del activador del factor nuclear- kappa- b (RANK), su ligando (RANKL) y la osteoprotegerina (OPG). Los glucocorticoides, recuentemente empleados en el tratamiento de la enfermedad renal crónica, exacerban este desequilibrio. En la enfermedad esclerótica renal, las moléculas de adhesión celular P-selectina and galectina-3 tienen un rol fundamental. El objetivo de esta trabajo fue estudiar las alteraciones en los mediadores de la remodelación ósea (RANKL, OPG, P-selectina and galectina-3) en un modelo de enfermedad renal crónica con tratamiento glucocorticoideo. Ratas Wistar hembras fueron divididos en 4 grupos: control (C); enfermedad renal crónica con afección de la remodelación ósea (ERC); animales con afección de la remodelación ósea expuestos a glucocorticoides (GC); enfermedad renal crónica con afección de la remodelación ósea tratados con glucocorticoides (ERC+GC). Los efectos de la ERC y los GC fueron evaluados bioquímicamente, histológicamente y por medición de la densidad ósea. RANKL, OPG, Pselectina and galectina-3 se cuantificaron en muestras de sangre venosa empleando enzimoinmuno análisis. En los 3 grupos experimentales la densidad ósea se evidenció reducida y los niveles séricos de RANKL elevados respecto al grupo control. Los niveles de OPG en los grupos ERC y GC fueron superiores mientras que en el grupo ERC+GC menores respecto a los animales controles. Galectina 3 plasmática en GC y ERC+GC se encontró reducida y aumentada en los animales ERC, en comparación con los animales controles. La concentración sérica de P-selectina sérica fue mayor en los grupos ERC y ERC+GC, y menor en los animales GC respecto a los niveles plasmáticos de los animales intactos. El avance del conocimiento sobre la regulación de la remodelación ósea a través de la interacción de mediadores sistémicos, en un futuro, puede conducir al desarrollo de nuevas estrategias terapéuticas para la prevención de la osteoporosis en pacientes con enfermedad renal crónica. (AU)
Descritores: Distúrbio Mineral e Ósseo na Doença Renal Crônica/induzido quimicamente
Remodelação Óssea/efeitos dos fármacos
Nefropatias/fisiopatologia
-Osteoporose/prevenção & controle
Doenças Ósseas Metabólicas/diagnóstico
Dexametasona/administração & dosagem
Densidade Óssea/efeitos dos fármacos
Clorofórmio/uso terapêutico
Ratos Wistar
Selectina-P/efeitos dos fármacos
Selectina-P/sangue
Galectina 3/efeitos dos fármacos
Galectina 3/sangue
Ligante RANK/efeitos dos fármacos
Ligante RANK/sangue
Osteoprotegerina/efeitos dos fármacos
Osteoprotegerina/sangue
Glucocorticoides/efeitos adversos
Glicerol/administração & dosagem
Nefropatias/tratamento farmacológico
Limites: Animais
Ratos
Tipo de Publ: Ensaio Clínico Controlado Aleatório Veterinário
Responsável: AR2.1 - Biblioteca Central


  2 / 9 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Costa Rica
Texto completo
Texto completo
Id: biblio-978346
Autor: Speranza Sánchez, M; Almonte, C; Castillo Chaves, G; Quesada Chaves, D; Effio, J; Frago, G; González, B; Molina, F; Núñez Ayala, E; Peralta López, E; Ramos Midence, C; Real, O; Ventura Umanzor, J.
Título: II Consenso Centroamericano y del Caribe de insuficiencia cardíaca biomarcadores séricos / II Central American and Caribbean Consensus on heart failure serum biomarkers
Fonte: Rev. costarric. cardiol;20(supl.2):4-10, dic. 2018. tab, graf.
Idioma: es.
Descritores: Biomarcadores
Comorbidade
América Central
Região do Caribe
Gerenciamento Clínico
Troponina T
Galectina 3
Peptídeos Natriuréticos/uso terapêutico
Cistatina C
Insuficiência Cardíaca
Limites: Humanos
Tipo de Publ: Conferência de Consenso
Responsável: CR1.1 - BINASSS - Biblioteca Nacional de Salud y Seguridad Social


  3 / 9 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1011117
Autor: Pasmatzi, Efstathia; Papadionysiou, Christina; Monastirli, Alexandra; Badavanis, George; Tsambaos, Dionysios.
Título: Galectin 3: an extraordinary multifunctional protein in dermatology. Current knowledge and perspectives
Fonte: An. bras. dermatol;94(3):348-354, May-June 2019. tab.
Idioma: en.
Resumo: Abstract: Galectin 3 is a unique ~31 kDa protein that recognizes the N-acetyl-lactosamine structure of several glycoconjugates. It mainly occurs in epithelial and myeloid cells, but is also found in a variety of human cell types. In view of the crucial role played by galectin 3 in the regulation of cellular processes of essential importance and in the pathogenetic mechanisms of diverse disorders, it is not surprising that, particularly in the last three decades, the attention of the scientific community has been increasingly drawn to this extraordinary and multifunctional galectin. In this paper the authors summarize current knowledge on the expression of galectin 3 in normal and diseased human skin, its implications in the pathogenesis, diagnosis and prognosis of cutaneous disorders, and the perspectives of a novel approach to the treatment of the latter using galectin 3 or its inhibitors/antagonists.
Descritores: Galectina 3/metabolismo
Galectina 3/uso terapêutico
Dermatite/metabolismo
-Dermatite/tratamento farmacológico
Dermatite/terapia
Amino Açúcares
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  4 / 9 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1003636
Autor: Fernández, J. Rodrigo; Ocaranza, María Paz; Herrera, Sebastián; Vega, Julián; Salinas, Manuel; Contreras-Briceño, Felipe; Llevaneras, Silvana; Jalil, Jorge E; Yañez, Fernando; Godoy, Paz; Córdova, Samuel; Chiong, Mario; Muñoz, Mario; Lavandero, Sergio; Castro, Pablo; Gabrielli, Luigi.
Título: Biomarcadores de fibrosis y función ventricular derecha en maratonistas con distinto grado de entrenamiento: estudio en la maratón de Santiago / Fibrosis and right ventricular function biomarkers in marathon runners: a study at the Santiago, Chile marathon
Fonte: Rev. chil. cardiol;38(1):37-45, abr. 2019. tab, graf.
Idioma: es.
Projeto: Fondecyt; . Fondap.
Resumo: Resumen: Introducción: Atletas altamente entrenados muestran cambios cardíacos estructurales como adaptación a la sobrecarga, producto del ejercicio repetitivo y extenuante. Se han evidenciado elevación de biomarcadores de remodelado y fibrosis miocárdica posterior al ejercicio intenso en atletas. Sin embargo, el comportamiento de estos biomarcadores según el nivel de entrenamiento previo no se ha evaluado. Objetivo: Investigar biomarcadores de fibrosis y función ventricular derecha en maratonistas con distinto nivel de entrenamiento previo. Métodos: Se incluyeron 36 maratonistas hombres, sanos, que completaron 42 km en la maratón de Santiago. Se dividieron según entrenamiento previo en dos grupos, Grupo 1 (G1): ≥100 km/semana y Grupo 2 (G2): <100 km/semana. Se realizó ecocardiografía transtorácica y se evaluaron niveles plasmáticos de galectina-3 y del propéptido amino terminal del procolágeno tipo III (PIIINP) en la semana previa a la carrera e inmediatamente posterior a ésta. Resultados: Posterior a la maratón, la función sistólica del ventrículo derecho disminuyó en el grupo G2 junto con un aumento significativo de los niveles plasmáticos de PIIIPNP (61±16 a 94±24 ng/mL, p=0,01). Estos cambios no se observaron en el grupo G1 (65 ± 11 a 90±29 ng/mL, p=0,10). Los niveles plasmáticos de galectina-3 aumentaron significativamente en ambos grupos posterior al ejercicio (6,8±2,2 a 19,7±4,9 ng/mL, p 0,012 y 6,0±1,1 a 19,4 ± 5,9 ng/mL, p 0,01) en los grupos G1 y G2, respectivamente). Conclusiones: Atletas con menor grado de entrenamiento, presentan posterior a una maratón un significativo aumento de productos de degradación del colágeno (PIIIPNP) asociado a disminución de la función del ventrículo derecho. Los niveles de galectina-3 plasmática aumentan significativamente en ambos grupos post-esfuerzo independiente del entrenamiento previo.

Abstracts: Introduction: Highly trained athletes show structural cardiac changes as adaptation to overload. Rise in remodeling biomarkers and myocardial fibrosis after intense exercise in athletes has been evidenced; however, the behavior of these biomarkers according to pre-competition training level has not been evaluated. Objective: To evaluate fibrosis biomarkers levels and right ventricle function in marathon runners according to their previous training level, in the period prior to a marathon race and immediately after it. Methods: Thirty-six healthy male marathon runners were included. Subjects were grouped according to their previous training level: Group 1 (G1): ≥100 km/week and Group 2 (G2): <100 km/week. Transthoracic echocardiography along with plasmatic levels of galectin-3 and amino terminal propeptide of type III procollagen (PIIINP) were measured one week previous and immediately after the marathon. Results: Post-effort right ventricle systolic function decreased in G2, together with a significant elevation of PIIIPNP (61±16 to 94±24 ng/mL, p=0.01). These changes were not observed in G1 (from 65±11 to 90±29 ng/mL, p=0.10). Plasma galectin-3 increased significantly in both groups immediately post-exercise (6.8±2.2 to 19.7±4.9 ng/mL, p=0.012, and 6.0±1.1 to 19.4±5.9 ng/mL, p=0.01, in G1 and G2. respectively). Conclusion: Less trained athletes evidenced higher post marathon levels of PIIIPNP which is associated with a decreased global right ventricle function. Plasma galectin-3 levels increased significantly after intense exertion regardless of the intensity of previous training.
Descritores: Corrida/fisiologia
Fibrose/sangue
Biomarcadores/sangue
Função Ventricular Direita
Traumatismos Cardíacos/sangue
-Fragmentos de Peptídeos/sangue
Fibrose/fisiopatologia
Exercício Físico/fisiologia
Método Simples-Cego
Chile
Estudos Prospectivos
Estudos Longitudinais
Função Ventricular Esquerda
Pró-Colágeno/sangue
Galectina 3/sangue
Atletas
Limites: Humanos
Masculino
Adulto
Pessoa de Meia-Idade
Responsável: CL126.2 - Biblioteca Médica Dr. Profesor Hernán Alessandri R.


  5 / 9 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1048544
Autor: Lopes, Rodrigo Guimarães.
Título: Impacto no metabolismo de células de câncer colorretal tratadas com pectinas de mamão papaia, in vitro, sob inibição química e bioquímica da expressão de GAL-3 / Impacts on the metabolism of colorectal cancer cells treated with papaya pectins, in vitro, under chemical and biochemical inhibition of GAL-3 expression.
Fonte: São Paulo; s.n; 2019. 81 p. graf, tab, ilus.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Faculdade de Ciências Farmacêuticas para obtenção do grau de Mestre.
Descritores: Técnicas In Vitro
Neoplasias Colorretais/tratamento farmacológico
Pectinas/administração & dosagem
Carica/imunologia
Galectina 3
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas
BR40.1; T641.34651, L864i. 30100022664-F


  6 / 9 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-782638
Autor: Gabrielli, Luigi; Verdejo, Hugo; Ocaranza, María Paz; Sepúlveda, Pablo; Baraona, Fernando; Salinas, Manuel; Saavedra, Rodrigo; Llevaneras, Silvana; Quiroga, Clara; Garayar, Bernardita; Lavandero, Sergio; Castro, Pablo.
Título: Remodelado auricular derecho y niveles plasmáticos de galectina-3 se relacionan con la capacidad funcional de pacientes con hipertensión arterial pulmonar / Right atrial remodeling and plasma leves of galectin-3 are related to functional capacity in patiensts with pulmonary artery hypertension
Fonte: Rev. chil. cardiol;35(1):19-24, 2016. tab.
Idioma: es.
Projeto: FON-DAP; . FONDECYT.
Resumo: Introducción: En pacientes con hipertensión arterial pulmonar (HAP) Galectina- 3, biomarcador de fibrosis miocárdica, se ha asociado a marcadores ecocardiográficos de remodelado ventricular derecho. La relación entre Galectina- 3, remodelado auricular derecho (AD) y capacidad funcional (CF) en pacientes con HAP no ha sido explorado. El objetivo fue medir niveles de Galectina-3 y su relación con CF y remodelado AD en pacientes con HAP Metodos: Estudio prospectivo observacional en que se incluyeron 14 pacientes con HAP En todos los pacientes se midieron los niveles de Galectina-3, proBNP, se evaluó la CF mediante test de caminata 6 minutos (TC6M) y se evaluó remodelado AD. Se consideraron para el análisis dos grupos según la distancia caminada en TC6M (> 200 m vs. ≤ 200 m). Resultados: La edad promedio fue 43 ± 10 años, el 84% mujeres. Los niveles de Galectina-3 fueron 16,1 ± 7,4 ng/mL y el TC6M fue 371 ± 142 mts. Los pacientes con TC6M< 200 m presentaron mayores niveles de Galectina-3 (27,3 ± 4,6 vs 13,7 ± 3,8; p=0,006) y mayor volumen AD (151 ± 21 vs 94 ± 43; p=0,04). Además, se observó una correlación inversa entre el área AD y TC6M (-0,71; p=0,03). Conclusión: Niveles elevados de Galectina-3 y parámetros de remodelado adverso en AD se relacionan con una menor CF en pacientes con HAP. Estos hallazgos apuntan a una mejor caracterización de pacientes con HAP y eventualmente la búsqueda de nuevos objetivos terapéuticos.

Background: Galectin-3 is a biomarker of myo-cardial fibrosis and has been associated with echocar-diographic markers of right ventricular remodeling in patients with pulmonary artery hypertension (PAH). The association among Galectin-3 level, right atrial (RA) remodeling and functional capacity (FC) has not been explored. The objective was to measure plasma Galectin-3 concentrations and its relation with RA remodeling and FC in PAH patients. Methods: This is a prospective observational study and 14 PAH patients were included. Galectin-3 and proBNP levels were measured in all patients. FC was estimated by the 6-minute walk test (6MWT) and used to define 2 groups of subjects (≤200m or >200m). RA area and volume were measured by echocardiography from a 4 chamber view. Results: The average age was 43±10 years, 84% of patients were female. Galectin-3 levels were 16.1±7.4 ng / mL and 6MWT was 371±142 m. We observed an inverse correlation between RA area and 6MWT (-0.71;p=0.03). Conclusions: Higher Galectin-3 concentrations and RA adverse remodeling are related to a decreased FC in PAH patients. These findings may lead to a better characterization of PAH patients and eventually new therapeutic targets.
Descritores: Artéria Pulmonar/fisiopatologia
Remodelação Ventricular
Galectina 3/sangue
Hipertensão Pulmonar/fisiopatologia
-Ecocardiografia
Biomarcadores
Estudos Prospectivos
Estudo Observacional
Hemodinâmica
Hipertensão Pulmonar/sangue
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: CL126.2 - Biblioteca Médica Dr. Profesor Hernán Alessandri R.


  7 / 9 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Mady, Charles
Texto completo
Id: biblio-988204
Autor: Antunes, Murillo de Oliveira; Arteaga-Fernández, Edmundo; Fernandes, Fábio; Soffiatti, Carla David; Buck, Paula de Cássia; Sabino, Ester Cerdeira; Moreira, Carlos Henrique Valente; Mady, Charles.
Título: Evaluation of Galectin-3 and myocardial fibrosis in patients with hypertrophic cardiomyopathy / Avaliação de Galectina-3 e fibrose miocárdica em pacientes com cardiomiopatia hipertrófica
Fonte: Int. j. cardiovasc. sci. (Impr.);32(2):152-157, mar.-abr. 2019. tab, graf.
Idioma: en.
Resumo: Background: Galectin-3 is the designation given to the protein that binds to ß-galactosides, expressed by activated macrophages and described as a cardiac fibrosis mediator. In hypertrophic cardiomyopathy (HCM), myocardial fibrosis is an independent predictor of adverse outcome; however, the association between Galectin-3 and myocardial fibrosis has not been studied in this cardiopathy. Objective: To evaluate the association of Galectin-3 and the presence of myocardial fibrosis in a patient with hypertrophic cardiomyopathy. Methods: Galectin-3 was measured in automated equipment using the Elisa technique in 100 participants divided into two groups: 50 patients with hypertrophic cardiomyopathy and 50 healthy control subjects. All patients with hypertrophic cardiomyopathy underwent magnetic nuclear resonance with the late enhancement technique to investigate myocardial fibrosis. For the statistical analysis, p values < 0.05 were considered statistically significant. Results: Galectin-3 levels were low and did not show significant differences between patients with hypertrophic cardiomyopathy and the control group,10.3 ± 3.1 ng/dL and 11.3 ± 2.6 ng/dL (p = 0.12) respectively. Myocardial fibrosis was a common finding and was identified in 84% (42/50) of patients with HCM, but no differences were observed between Galectin-3 levels when comparing patients with and without fibrosis, 10.3 ± 2.4 ng/dL and 10.1 ± 2.1 ng/dL (p = 0.59). Conclusion: The results did not show an association between Galectin-3 and myocardial fibrosis in patients with hypertrophic cardiomyopathy, suggesting that non-inflammatory mechanisms of myocardial fibrosis formation and cardiac remodeling are involved in this cardiopathy
Descritores: Cardiomiopatia Hipertrófica/diagnóstico por imagem
Galectina 3
Fibrose Endomiocárdica
-Arritmias Cardíacas/diagnóstico
Diagnóstico por Imagem/métodos
Espectroscopia de Ressonância Magnética/métodos
Biomarcadores
Doenças Cardiovasculares/diagnóstico
Ecocardiografia Doppler/métodos
Análise Estatística
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Responsável: BR44.1 - Serviço de Biblioteca, Documentação Científica e Didática Prof. Dr. Luiz Venere Décourt


  8 / 9 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-839281
Autor: Li, M; Feng, YM; Fang, SQ.
Título: Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;50(4):e5356, 2017. tab, graf.
Idioma: en.
Resumo: The aim of this study was to explore the correlation of ezrin and galectin-3 expressions with prognosis in cervical cancer. The immunohistochemical method was applied to detect ezrin and galectin-3 expressions in normal cervix tissues (n=30), cervicitis tissues (n=28), cervical intraepithelial neoplasia (CIN) tissues (classified as I-III, n=89), and cervical carcinoma tissues (n=84). Follow-up was conducted for 5 to 78 months to analyze the correlation of protein expressions with prognosis. Ezrin and galectin-3 expressions in cervical cancer were significantly higher than in normal cervix, cervicitis and CIN (all P<0.05), and expressions in CIN were significantly higher than in normal cervix and cervicitis (both P<0.05). The expressions of ezrin and galectin-3 were both related with histological grade, deep myometrial invasion and lymph node metastasis (all P<0.05). Spearman analysis showed that ezrin expression was positively correlated with galectin-3 expression in cervical cancer (r=0.355, P<0.05). The survival rate of patients with high expressions of ezrin and galectin-3 was significantly lower than those with low expressions of proteins (both P<0.05). The expressions of ezrin and galectin-3, histological grade, depth of stromal invasion, and lymph node metastasis are risk factors affecting the survival rate of patients with cervical cancer. The expressions of ezrin and galectin-3 were correlated with the development of cervical cancer, and overexpressions of those proteins were indicative of poor prognosis in patients with cervical cancer.
Descritores: Adenocarcinoma/metabolismo
Carcinoma Adenoescamoso/metabolismo
Carcinoma de Células Escamosas/metabolismo
Neoplasia Intraepitelial Cervical/metabolismo
Proteínas do Citoesqueleto/metabolismo
Galectina 3/metabolismo
Neoplasias do Colo do Útero/metabolismo
-Imuno-Histoquímica
Estimativa de Kaplan-Meier
Linfonodos/metabolismo
Metástase Linfática
Prognóstico
Modelos de Riscos Proporcionais
Valores de Referência
Fatores de Tempo
Limites: Humanos
Feminino
Adulto
Responsável: BR1.1 - BIREME


  9 / 9 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-787063
Autor: Özdenoglu, Berna; Saraydin, Serpil Ünver.
Título: Does diabetes alter immunolocalization of galectin-1 and galectin-3 in the rat ovary? / ¿La diabetes altera la inmunolocalización de galectina-1 y galectina-3 en el ovario de rata?
Fonte: Int. j. morphol;34(2):742-751, June 2016. ilus.
Idioma: en.
Resumo: Diabetes mellitus (DM), is a metabolic disease occurring via insulin secretion deficiency from the pancreas and/or an insufficiency of tissue response to insulin. The present study is intended to show of immunolocalizations of beta-galactose-binding proteins Galectin-1 and Galectin-3 in diabetic rat ovarium and their relationship with diabetes. In this study, 8 to 10-week-old, 250­300 g weighing 50 mature female rats were used, in order to establish diabetes mellitus in those animals, 60 mg/kg intravenous streptozotocin was injected to each animal. After death, diabetics and non-diabetics rats's routine tissue processing steps is done to rat ovarial tissues for immunohistochemical investigation. Strong expressions of Galectin-1 and Galectin-3 were observed in the ovarial germinal epithelium and vascular endothelial. While the strong intense expression of Galectin-1 was seen in the zona pellucida, Galectin-3 expression was strongest in the cytoplesmic regions of cells. Zona pellucida has 3 protein complexes (ZP1, ZP2 and ZP3) in rats and in humans and they have the capability of recognizing the carbonhydrate fields in tissues. The strong expression of galectins in those regions could be the result of carbonhydrate binding properties expression of Gal-3 in the cytoplasmic regions of growing follicles could suggest the idea that Gal-3 could have effects on follicle growth. In conclusion, beta galactose-binding proteins Gal-1 and Gal-3 had stronger immunolocalization in diabetic rat ovarium when compared to the controls. Diabetes could increase the Gal-1 and Gal-3 expressions in the ovarial tissue.

La diabetes mellitus (DM) es una enfermedad metabólica debido a una deficiencia en la secreción de insulina por parte del páncreas o por una insuficiente respuesta de los tejidos a la insulina. El objetivo fue demostrar la inmunolocalización de las proteínas de unión beta-galactosa Galectina-1 y Galectina-3 en los ovarios de ratas diabéticas y su relación con la diabetes. Fueron utilizadas 50 ratas hembras maduras entre 8­10 semanas de edad, con un peso de 250­300 g. Con el fin de desarrollar DM en los animales, se inyectó a cada uno 60 mg/kg de estreptozotocina vía intravenosa. Después de la eutanasia, se realizó el procesamiento de rutina de los tejidos de las ratas diabéticas y no diabéticas para evaluar los tejidos ováricosa través de inmunohistoquímica. Se observaron expresiones fuertes de la Galectina-1 y Galectina-3 en el epitelio germinal y epitelio endotelial vascular del ovario. Si bien la fuerte e intensa expresión de Galectina-1 se observó en la zona pelúcida, la Galectina-3 tuvo una expresión más fuerte en las regiones de las células citoplasmáticas. La zona pelúcida tiene 3 complejos de proteínas (ZP1, ZP2 y ZP3) en ratas y en seres humanos y tienen la capacidad de reconocer los campos de carbohidratos en los tejidos. La fuerte expresión de las galectinas de esas regiones podría ser el resultado de las propiedades de unión a carbonhidratos expresión de Gal-3 en las regiones citoplasmáticas de los folículos en crecimiento, pudiendo sugerir que Gal-3 podría tener efectos sobre el crecimiento del folículo. En conclusión, las proteínas de unión beta-galactosa Gal-1 y Gal-3 tienen una mayor inmunolocalización en los ovarios de ratas diabéticas, en comparación a los controles. La diabetes podría incrementar las expresiones de Gal-1 y Gal-3 en el tejido ovárico.
Descritores: Diabetes Mellitus/metabolismo
Galectina 1/metabolismo
Galectina 3/metabolismo
Ovário/metabolismo
-Imuno-Histoquímica
Limites: Animais
Feminino
Ratos
Responsável: CL1.1 - Biblioteca Central



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde